BidaskClub upgraded shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) from a hold rating to a buy rating in a research note released on Thursday, July 6th.

Other equities analysts have also recently issued reports about the company. Robert W. Baird increased their price target on Achillion Pharmaceuticals from $5.00 to $10.00 and gave the company an outperform rating in a report on Monday, April 24th. TheStreet cut Achillion Pharmaceuticals from a c- rating to a d rating in a report on Wednesday, March 22nd. Leerink Swann raised Achillion Pharmaceuticals from a market perform rating to an outperform rating and raised their target price for the stock from $4.00 to $6.00 in a report on Thursday, May 18th. Jefferies Group LLC reaffirmed a hold rating on shares of Achillion Pharmaceuticals in a report on Wednesday, April 26th. Finally, Maxim Group decreased their target price on Achillion Pharmaceuticals from $8.00 to $5.00 and set a buy rating on the stock in a report on Tuesday, April 25th. One analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus price target of $8.75.

Shares of Achillion Pharmaceuticals (NASDAQ ACHN) traded up 1.03% during mid-day trading on Thursday, reaching $3.94. The company had a trading volume of 758,407 shares. The company has a 50 day moving average price of $4.40 and a 200 day moving average price of $4.12. Achillion Pharmaceuticals has a one year low of $3.15 and a one year high of $9.49. The company’s market capitalization is $538.69 million.

Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.01. During the same period in the previous year, the company earned ($0.13) EPS. On average, analysts anticipate that Achillion Pharmaceuticals will post ($0.64) EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Achillion Pharmaceuticals, Inc. (ACHN) Stock Rating Upgraded by BidaskClub” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another website, it was stolen and reposted in violation of U.S. and international copyright law. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/08/04/bidaskclub-upgrades-achillion-pharmaceuticals-inc-achn-to-buy-updated-updated-updated.html.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Legal & General Group Plc raised its position in Achillion Pharmaceuticals by 53.8% in the second quarter. Legal & General Group Plc now owns 42,900 shares of the biopharmaceutical company’s stock valued at $196,000 after buying an additional 15,000 shares in the last quarter. Bank of New York Mellon Corp raised its position in Achillion Pharmaceuticals by 11.4% in the second quarter. Bank of New York Mellon Corp now owns 611,634 shares of the biopharmaceutical company’s stock valued at $2,808,000 after buying an additional 62,515 shares in the last quarter. Alps Advisors Inc. raised its position in Achillion Pharmaceuticals by 5.0% in the second quarter. Alps Advisors Inc. now owns 123,412 shares of the biopharmaceutical company’s stock valued at $566,000 after buying an additional 5,824 shares in the last quarter. SG Americas Securities LLC raised its position in Achillion Pharmaceuticals by 18.6% in the second quarter. SG Americas Securities LLC now owns 26,429 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 4,144 shares in the last quarter. Finally, State of Wisconsin Investment Board bought a new position in Achillion Pharmaceuticals during the second quarter valued at approximately $390,000. Institutional investors own 71.24% of the company’s stock.

Achillion Pharmaceuticals Company Profile

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Analyst Recommendations for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Stock Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.